With FDA all-clear, Soligenix to move oral mucositis candidate into pivotal study

After a year of gathering feedback from regulators following completion of its phase II study, Soligenix Inc. said it reached accord with the FDA to advance SGX-942 into a pivotal phase III study to treat oral mucositis in head and neck cancer patients treated with chemoradiation.